184 related articles for article (PubMed ID: 22001740)
1. Omenn syndrome does not live by V(D)J recombination alone.
Marrella V; Maina V; Villa A
Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):525-31. PubMed ID: 22001740
[TBL] [Abstract][Full Text] [Related]
2. [Omenn Syndrome and DNA recombination defects].
Yachie A
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(3):179-189. PubMed ID: 28747605
[TBL] [Abstract][Full Text] [Related]
3. Similar recombination-activating gene (RAG) mutations result in similar immunobiological effects but in different clinical phenotypes.
IJspeert H; Driessen GJ; Moorhouse MJ; Hartwig NG; Wolska-Kusnierz B; Kalwak K; Pituch-Noworolska A; Kondratenko I; van Montfrans JM; Mejstrikova E; Lankester AC; Langerak AW; van Gent DC; Stubbs AP; van Dongen JJ; van der Burg M
J Allergy Clin Immunol; 2014 Apr; 133(4):1124-33. PubMed ID: 24418478
[TBL] [Abstract][Full Text] [Related]
4. More than just SCID--the phenotypic range of combined immunodeficiencies associated with mutations in the recombinase activating genes (RAG) 1 and 2.
Niehues T; Perez-Becker R; Schuetz C
Clin Immunol; 2010 May; 135(2):183-92. PubMed ID: 20172764
[TBL] [Abstract][Full Text] [Related]
5. Partial V(D)J recombination activity leads to Omenn syndrome.
Villa A; Santagata S; Bozzi F; Giliani S; Frattini A; Imberti L; Gatta LB; Ochs HD; Schwarz K; Notarangelo LD; Vezzoni P; Spanopoulou E
Cell; 1998 May; 93(5):885-96. PubMed ID: 9630231
[TBL] [Abstract][Full Text] [Related]
6.
Chen R; Lukianova E; van der Loeff IS; Spegarova JS; Willet JDP; James KD; Ryder EJ; Griffin H; IJspeert H; Gajbhiye A; Lamoliatte F; Marin-Rubio JL; Woodbine L; Lemos H; Swan DJ; Pintar V; Sayes K; Ruiz-Morales ER; Eastham S; Dixon D; Prete M; Prigmore E; Jeggo P; Boyes J; Mellor A; Huang L; van der Burg M; Engelhardt KR; Stray-Pedersen A; Erichsen HC; Gennery AR; Trost M; Adams DJ; Anderson G; Lorenc A; Trynka G; Hambleton S
Sci Immunol; 2024 May; 9(95):eade5705. PubMed ID: 38787962
[TBL] [Abstract][Full Text] [Related]
7. Omenn syndrome in the context of other B cell-negative severe combined immunodeficiencies.
Villa A; Sobacchi C; Vezzoni P
Isr Med Assoc J; 2002 Mar; 4(3):218-21. PubMed ID: 11908269
[TBL] [Abstract][Full Text] [Related]
8. The genetic and biochemical basis of Omenn syndrome.
Santagata S; Villa A; Sobacchi C; Cortes P; Vezzoni P
Immunol Rev; 2000 Dec; 178():64-74. PubMed ID: 11213808
[TBL] [Abstract][Full Text] [Related]
9. Human RAG mutations: biochemistry and clinical implications.
Notarangelo LD; Kim MS; Walter JE; Lee YN
Nat Rev Immunol; 2016 Apr; 16(4):234-46. PubMed ID: 26996199
[TBL] [Abstract][Full Text] [Related]
10. A systematic analysis of recombination activity and genotype-phenotype correlation in human recombination-activating gene 1 deficiency.
Lee YN; Frugoni F; Dobbs K; Walter JE; Giliani S; Gennery AR; Al-Herz W; Haddad E; LeDeist F; Bleesing JH; Henderson LA; Pai SY; Nelson RP; El-Ghoneimy DH; El-Feky RA; Reda SM; Hossny E; Soler-Palacin P; Fuleihan RL; Patel NC; Massaad MJ; Geha RS; Puck JM; Palma P; Cancrini C; Chen K; Vihinen M; Alt FW; Notarangelo LD
J Allergy Clin Immunol; 2014 Apr; 133(4):1099-108. PubMed ID: 24290284
[TBL] [Abstract][Full Text] [Related]
11. Lack of iNKT cells in patients with combined immune deficiency due to hypomorphic RAG mutations.
Matangkasombut P; Pichavant M; Saez DE; Giliani S; Mazzolari E; Finocchi A; Villa A; Sobacchi C; Cortes P; Umetsu DT; Notarangelo LD
Blood; 2008 Jan; 111(1):271-4. PubMed ID: 17890453
[TBL] [Abstract][Full Text] [Related]
12. HyperIgE in hypomorphic recombination-activating gene defects.
Castiello MC; Brandas C; Capo V; Villa A
Curr Opin Immunol; 2023 Feb; 80():102279. PubMed ID: 36529093
[TBL] [Abstract][Full Text] [Related]
13. Characterization of immune function and analysis of RAG gene mutations in Omenn syndrome and related disorders.
Wada T; Takei K; Kudo M; Shimura S; Kasahara Y; Koizumi S; Kawa-Ha K; Ishida Y; Imashuku S; Seki H; Yachie A
Clin Exp Immunol; 2000 Jan; 119(1):148-55. PubMed ID: 10606976
[TBL] [Abstract][Full Text] [Related]
14. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations.
Villa A; Sobacchi C; Notarangelo LD; Bozzi F; Abinun M; Abrahamsen TG; Arkwright PD; Baniyash M; Brooks EG; Conley ME; Cortes P; Duse M; Fasth A; Filipovich AM; Infante AJ; Jones A; Mazzolari E; Muller SM; Pasic S; Rechavi G; Sacco MG; Santagata S; Schroeder ML; Seger R; Strina D; Ugazio A; Väliaho J; Vihinen M; Vogler LB; Ochs H; Vezzoni P; Friedrich W; Schwarz K
Blood; 2001 Jan; 97(1):81-8. PubMed ID: 11133745
[TBL] [Abstract][Full Text] [Related]
15. Analysis of mutations and recombination activity in RAG-deficient patients.
Asai E; Wada T; Sakakibara Y; Toga A; Toma T; Shimizu T; Nampoothiri S; Imai K; Nonoyama S; Morio T; Muramatsu H; Kamachi Y; Ohara O; Yachie A
Clin Immunol; 2011 Feb; 138(2):172-7. PubMed ID: 21131235
[TBL] [Abstract][Full Text] [Related]
16. Omenn syndrome: a disorder of Rag1 and Rag2 genes.
Villa A; Santagata S; Bozzi F; Imberti L; Notarangelo LD
J Clin Immunol; 1999 Mar; 19(2):87-97. PubMed ID: 10226883
[TBL] [Abstract][Full Text] [Related]
17. Oligoclonal expansion of T lymphocytes with multiple second-site mutations leads to Omenn syndrome in a patient with RAG1-deficient severe combined immunodeficiency.
Wada T; Toma T; Okamoto H; Kasahara Y; Koizumi S; Agematsu K; Kimura H; Shimada A; Hayashi Y; Kato M; Yachie A
Blood; 2005 Sep; 106(6):2099-101. PubMed ID: 15845893
[TBL] [Abstract][Full Text] [Related]
18. Mutations in CHD7 in patients with CHARGE syndrome cause T-B + natural killer cell + severe combined immune deficiency and may cause Omenn-like syndrome.
Gennery AR; Slatter MA; Rice J; Hoefsloot LH; Barge D; McLean-Tooke A; Montgomery T; Goodship JA; Burt AD; Flood TJ; Abinun M; Cant AJ; Johnson D
Clin Exp Immunol; 2008 Jul; 153(1):75-80. PubMed ID: 18505430
[TBL] [Abstract][Full Text] [Related]
19. Clinical, immunologic, and genetic characteristics of RAG mutations in 15 Chinese patients with SCID and Omenn syndrome.
Bai X; Liu J; Zhang Z; Liu C; Zhang Y; Tang W; Dai R; Wu J; Tang X; Zhang Y; Ding Y; Jiang L; Zhao X
Immunol Res; 2016 Apr; 64(2):497-507. PubMed ID: 26476733
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of lentivirus-mediated gene therapy in an Omenn syndrome recombination-activating gene 2 mouse model is not hindered by inflammation and immune dysregulation.
Capo V; Castiello MC; Fontana E; Penna S; Bosticardo M; Draghici E; Poliani LP; Sergi Sergi L; Rigoni R; Cassani B; Zanussi M; Carrera P; Uva P; Dobbs K; Sacchetti N; Notarangelo LD; van Til NP; Wagemaker G; Villa A
J Allergy Clin Immunol; 2018 Sep; 142(3):928-941.e8. PubMed ID: 29241731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
